Logo image of BTLS.BR

BIOTALYS NV (BTLS.BR) Stock Fundamental Analysis

Europe - EBR:BTLS - BE0974386188 - Common Stock

4.63 EUR
-0.13 (-2.73%)
Last: 11/19/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, BTLS scores 2 out of 10 in our fundamental rating. BTLS was compared to 69 industry peers in the Chemicals industry. The financial health of BTLS is average, but there are quite some concerns on its profitability. BTLS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BTLS has reported negative net income.
In the past year BTLS has reported a negative cash flow from operations.
In the past 5 years BTLS always reported negative net income.
BTLS had a negative operating cash flow in each of the past 5 years.
BTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFBTLS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

BTLS's Return On Assets of -51.17% is on the low side compared to the rest of the industry. BTLS is outperformed by 92.75% of its industry peers.
With a Return On Equity value of -74.20%, BTLS is not doing good in the industry: 88.41% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -51.17%
ROE -74.2%
ROIC N/A
ROA(3y)-45.93%
ROA(5y)-38.31%
ROE(3y)-62.28%
ROE(5y)-51.5%
ROIC(3y)N/A
ROIC(5y)N/A
BTLS.BR Yearly ROA, ROE, ROICBTLS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

BTLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTLS.BR Yearly Profit, Operating, Gross MarginsBTLS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

BTLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BTLS has more shares outstanding
The debt/assets ratio for BTLS has been reduced compared to a year ago.
BTLS.BR Yearly Shares OutstandingBTLS.BR Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BTLS.BR Yearly Total Debt VS Total AssetsBTLS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

BTLS has an Altman-Z score of 9.80. This indicates that BTLS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BTLS (9.80) is better than 98.55% of its industry peers.
BTLS has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BTLS (0.16) is better than 72.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 9.8
ROIC/WACCN/A
WACCN/A
BTLS.BR Yearly LT Debt VS Equity VS FCFBTLS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

BTLS has a Current Ratio of 3.59. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
BTLS has a Current ratio of 3.59. This is amongst the best in the industry. BTLS outperforms 91.30% of its industry peers.
BTLS has a Quick Ratio of 3.59. This indicates that BTLS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BTLS (3.59) is better than 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.59
BTLS.BR Yearly Current Assets VS Current LiabilitesBTLS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.61% over the past year.
EPS 1Y (TTM)19.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BTLS will show a small growth in Earnings Per Share. The EPS will grow by 0.29% on average per year.
Based on estimates for the next years, BTLS will show a quite strong growth in Revenue. The Revenue will grow by 10.43% on average per year.
EPS Next Y1.76%
EPS Next 2Y14.71%
EPS Next 3Y0.29%
EPS Next 5YN/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A

3.3 Evolution

BTLS.BR Yearly Revenue VS EstimatesBTLS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2023 2024 2025 2026 2027 2M 4M 6M
BTLS.BR Yearly EPS VS EstimatesBTLS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BTLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTLS.BR Price Earnings VS Forward Price EarningsBTLS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTLS.BR Per share dataBTLS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.71%
EPS Next 3Y0.29%

More info and screens

0

5. Dividend

5.1 Amount

BTLS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOTALYS NV

EBR:BTLS (11/19/2025, 7:00:00 PM)

4.63

-0.13 (-2.73%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)09-18 2025-09-18
Earnings (Next)N/A N/A
Inst Owners21.69%
Inst Owner ChangeN/A
Ins Owners4.84%
Ins Owner ChangeN/A
Market Cap173.72M
Revenue(TTM)N/A
Net Income(TTM)-14.84M
Analysts86.67
Price Target7.58 (63.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.89%
EPS NY rev (3m)53.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.76
P/tB 9.01
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS0.53
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.17%
ROE -74.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.93%
ROA(5y)-38.31%
ROE(3y)-62.28%
ROE(5y)-51.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.59
Altman-Z 9.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.08%
Cap/Depr(5y)109.32%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y1.76%
EPS Next 2Y14.71%
EPS Next 3Y0.29%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-52%
Revenue Next 2Y3.92%
Revenue Next 3Y10.43%
Revenue Next 5YN/A
EBIT growth 1Y9.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.38%
EBIT Next 3Y-3.79%
EBIT Next 5YN/A
FCF growth 1Y35.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.08%
OCF growth 3YN/A
OCF growth 5YN/A

BIOTALYS NV / BTLS.BR FAQ

What is the ChartMill fundamental rating of BIOTALYS NV (BTLS.BR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BTLS.BR.


What is the valuation status for BTLS stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOTALYS NV (BTLS.BR). This can be considered as Overvalued.


Can you provide the profitability details for BIOTALYS NV?

BIOTALYS NV (BTLS.BR) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for BTLS stock?

The Earnings per Share (EPS) of BIOTALYS NV (BTLS.BR) is expected to grow by 1.76% in the next year.